TB facility assessment sheet

|  |  |  |
| --- | --- | --- |
| **Access to care** | Free TB and HIV diagnosis and treatment |  |
| HIV services in TB facility |  |
| **Patient comfort and support** | Adequate comfort for inpatients (heating, blankets, fans, cleanliness, etc.) |  |
| Adequate food supply for inpatients |  |
| Supplementary rations for outpatients available (when appropriate) |  |
| Bed occupancy rate of TB ward ≤ 100% |  |
| Patient support provided according to local eligibility criteria |  |
| **Hygiene** | Adequate cleaning supplies and protocols |  |
| Adequate waste management (incinerator, safety boxes, etc.) and protocols (sorting, etc.) |  |
| **Adherence** | Therapeutic patient education sessions scheduled and delivered |  |
| SAT available when appropriate |  |
| DOT available when appropriate |  |
| % of patients attending their appointments for drug delivery out of number of patients expected (on a random sample of days) |  |
| Adherence rate calculated for patients taking their treatment under DOT (on a random sample of patients) |  |
| Adequate system for identifying patients who interrupted treatment |  |
| % of patients who interrupted treatment contacted to resume their treatment |  |
| % of patients who resumed treatment after being contacted |  |
| **Pharmacy** | One person in charge of pharmacy |  |
| TB drugs from WHO-prequalified sources (or equivalent) |  |
| FDCs and paediatric formulations available |  |
| 3-month buffer stock of TB drugs |  |
| Stock cards updated |  |
| Absence of drug shortage(s) during the last quarter |  |
| Adequate storage conditions |  |

|  |  |  |
| --- | --- | --- |
| **Laboratory** | 3-month buffer stock of laboratory supplies |  |
| Absence of shortage(s) of laboratory supplies during the last quarter |  |
| External quality assurance (EQA) of smear microscopy performed and results according to standards |  |
| Annual EQA of DST performed and results according to standards |  |
| **Contact screening** | % of known contacts screened for active TB |  |
| % of contacts screening positive referred for active TB diagnosis |  |
| % of contacts screening negative referred for diagnosis and/or treatment of LTBI |  |
| **Diagnosis** | Use of Xpert MTB/RIF (or Ultra) |  |
| Use of Xpert MTB/XDR |  |
| Use of culture and pDST |  |
| Use of genome sequencing |  |
| Use of LF-LAM |  |
| Use of X-rays |  |
| Use of alternative specimen collection methods for children (e.g. stool, sputum induction, nasopharyngeal aspirate) |  |
| **Treatment and follow-up** | % of patients correctly treated, including combinations, doses, duration (on a random sample of patients) |  |
| % of patients who had bacteriological follow-up according to schedule (on a random sample of patients) |  |
| % of patients with MDR/RR-TB who had other investigations (e.g. ECG, BPNS) according to schedule (on a random sample of patients) |  |
| **Recording tools** | Consistency between TB registers and individual TB treatment cards |  |
| Consistency between TB and laboratory registers |  |
| **Standard case definitions** | % of patients registered with an accurate case definition (on a random sample of patients) |  |
| **Criteria for cure** | % of bacteriologically confirmed PTB cases declared cured who meet the definition of "cured" (on a random sample of patients) |  |
| **Staff** | Job descriptions (clinicians, nurses, lab technicians, cleaning staff, etc.) available and updated |  |
| Training sessions scheduled and delivered |  |